PregnancyNCT02593214
Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®)
A study testing Wondaleaf® in people with Pregnancy and Sexually Transmitted Disease, run by Clinical Research Centre, Malaysia at 1 site in Malaysia.
Trial summary
General objective: To assess the performance and safety profile of a novel innovative design of female condom (Wondaleaf®) among healthy married women. Specific objectives : To determine the failure rate of Wondaleaf®, in terms of clinical breakage, non-clinical breakage, invagination, misdirection, and slippage. Read more about this study
- Who is it for?
- Ages 21 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Pregnancy, Sexually Transmitted Disease
- What is being tested?
- Wondaleaf®
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteMalaysia
- Study dates
- Aug 2015to Sep 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Sexually active and legally married couples both between 21 and 45 years of age, and who have been in sexual relationship for at least 6 months;
- Married couples who are willing to participate (i.e. maintain sexually active and agree to have penile-vaginal intercourse with frequency sufficient to meet protocol requirements) and having signed informed consent form;
- Married women willing to have physical examination of the genitalia by the investigator (who is a medical doctor);
- Married women who are willing to take urine pregnancy test;
- Married couples who are planning to get pregnant, but do not mind delaying it;
- Married couples who are not planning for pregnancy soon, yet do not mind getting pregnant (however if found pregnant during the study period, study for the couple will be terminated);
Show all 14Show fewer
- Married woman and/or her spouse who are on effective contraception (e.g. oral contraceptive, intrauterine device, injectable, patch), or female / male sterilisation methods before entering the study and able to maintain the contraception throughout the study period;
- Married couples who agree to use only study female condom during the time of participation;
- Married couples who are able to understand instructions for correct use of study female condoms;
- Married couples who agree not to use male condom when using the study female condom in a single sexual intercourse;
- Married couples who agree not to use drugs or non-study devices that affect sexual performance;
- Married couples who agree not to wear any genital piercing jewellery while using study female condoms;
- Literate married couple who can complete the study questionnaire and coital log on their own in language of their choice (English, Chinese, or Malay);
- Married couples who are able to comply with completing questionnaire and coital log, as well as attending all study visits.
Who cannot join
- Female subject with known history of untreated or suspected sexually transmitted infection(s) including HIV/AIDS, vaginal or uterine infection(s), and/or urinary tract infections;
- Female subject with a history of abnormal Pap smear or cervical / uterine diseases;
- Female subject who is pregnant (established by urine pregnancy test), or desires to become so while participating in study;
- Either one of the married couple who have known history of allergy to the devices or materials used to manufacture the investigational devices, or any female or male condom, or lubricants that are used on the devices;
- Those staff who work directly under the investigators and/or employed directly by the device manufacturers, sponsor and study team;
- Female subject who have menopausal symptom (12 months history with no bleeding unless because of contraceptive methods);
Show all 16Show fewer
- Male subject who has known erectile or ejaculatory dysfunction;
- Either one of the married couple who had history of hospitalisation because of acute illness within three months before Visit 1;
- Either one of the married couple is using any medications or preparation applied topically or intravaginal to the genitalia, other than that supplied for the study (subjects can be rescreened 14 days after the recovery, if the application are for acute illness);
- Any married couple who have received advice from their medical doctor for not engaging in sexual intercourse during the intended study period because of their health conditions, which may include chronic disease or chronic administration (defined as more than 14 days in total) of any medicine, based on medical history and physical examination (no laboratory testing required);
- Women subject and/or their spouse taking medicine which is known to influence sexual performance / libido, or to cause impotence, for any reasons, 30 days before visit 1, and during the intended study period (no laboratory testing required);
- Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as axillary / tympanic / rectal temperature ≥ 38°C. Subjects can be rescreened 14 days after the recovery;
- Active untreated tuberculosis or communicable diseases of the women subjects and/or their spouse based on medical history;
- Blood dyscrasias, bleeding disorder, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems;
- . The couple concurrently participating in another clinical study involving female and/or male condom;
- Presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system(s) or psychiatric disease or other conditions that may interfere with the health conditions (such as in case the women subject become pregnant), or would place the subjects at increased risk, as determined by the investigator(s).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Trial to Asses the Performance and Safety of an Innovative Female Condom (Wondaleaf®) Among Healthy Married Couples
General objective:
To assess the performance and safety profile of a novel innovative design of female condom (Wondaleaf®) among healthy married women.
Specific objectives :
- To determine the failure rate of Wondaleaf®, in terms of clinical breakage, non-clinical breakage, invagination, misdirection, and slippage.
- To determine the acceptability and satisfaction of use of Wondaleaf® by subjects and their spouses.
- To assess the safety profile of Wondaleaf®.
Read the detailed description
This is a single-centre clinical trial to assess the performance and safety profile of Wondaleaf® in healthy married women. Referrals from doctors and nurses in the Maternal and Child Health Clinics, Family Planning Clinics and private clinics in Sibu will be received. A total of 63 couples will be recruited to use Wondaleaf® and to study self-reported total clinical failure and total female condom failure and their components failure events of clinical breakage, non-clinical breakage, total breakage, slippage, misdirection, and invagination (as per World Health Organisation (WHO) Female Condom Technical Review Committee definition(1)). Secondary outcomes were safety parameters (retention of investigational device intra-vaginally should it break, complaint of sexually transmitted diseases, vaginal infection and/or urinary tract infections, all adverse events, serious adverse events, adverse device events and serious adverse device events, allergic reaction) as well as acceptability and satisfaction of the use of Wondaleaf®.
A focus group discussion will be held for the first two couples, to a maximum of five couples recruited based on the same inclusion and exclusion criteria will be asked to trial the process of training / counselling of using the condom, as well as completing the coital log. Experience gathered from these focus group testing and discussion, will be used to enhance the strength of this protocol.
Subsequently, each couple will be asked to use five Wondaleaf® and to complete a coital log at home after each condom use. Before putting on the investigational device, the subject must check for device or package breakage. During sexual intercourse, the couple ought to notice if any breakage of the condom has occurred, and if the female condom slips completely out of the vagina or the penis of male spouse is inserted between the condom and the vaginal wall as well as event of invagination (when the external retention feature of the female condom is partly or fully pushed into the vagina).
Each subject must maintain the wearing of investigational device for the entire process of intercourse until the male spouse ejaculate intra-vaginally. Following each ejaculation of the male spouse, the investigational devices must be checked for breakage before, during and after withdrawal of the condom from the vagina. A coital log must be completed by the couples within 12 hours after the use of each investigational device. Coital logs are used to obtain data for condom performance and safety. The five female investigational devices should be used within a period of four weeks. The used investigational devices shall be discarded safely in the usual and safe manner at home.
After the women completed five uses of Wondaleaf® or after four weeks (whichever occurs first), they will return to the clinic to return their coital log and to fill out an acceptability and satisfaction questionnaire. Any unused female investigational devices (i.e. the female condom) will be returned for counting purposes.
If the women were confirmed pregnant during study period, the subjects will be withdrawn from the study. The married couple will be referred for antenatal care of their choice.
- Conditions
- Pregnancy, Sexually Transmitted Disease
- Being tested
- Wondaleaf®
- Keywords
- Condoms, Female, Contraception, Barrier
- Medical subject headings
- Sexually Transmitted Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wondaleaf®Device
Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
| Study group | Role | What they receive |
|---|---|---|
| Wondaleaf Arm | Experimental | This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only. Receives: Device: Wondaleaf® |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total female condom failure
Number of times a non-clinical breakage, clinical breakage, or slippage occurs, or that is associated with misdirection, invagination, or any additional failure modes identified in the risk assessment
Measured: Five uses of investigational devices, an average of one month
Secondary outcomes (10)
Total clinical failure
the numbers of female condoms that clinically break or slip, or that are associated with misdirection, invagination, or any additional failure modes identified in the risk assessment, which result in reduction of the protective function of the condom.
Measured: Five uses of investigational devices, an average of one month
Clinical breakage
The number of times a breakage of the condom during sexual intercourse or during withdrawal of the female condom from the vagina (potential adverse clinical consequences) occurs
Measured: Five uses of investigational devices, an average of one month
Non-clinical breakage
Number of times a breakage is noticed before intercourse or occurring after withdrawal of the condom from the vagina (no potential adverse clinical consequences)
Measured: Five uses of investigational devices, an average of one month
Total breakage
the number of all condom breakages at any time before, during, or after sexual intercourse; includes both clinical and non-clinical breakages
Measured: Five uses of investigational devices, an average of one month
Slippage
Number of times when a female condom slips completely out of the vagina during sexual intercourse
Measured: Five uses of investigational devices, an average of one month
Misdirection
Number of times a vaginal penetration whereby the penis is inserted between the condom and the vaginal wall occurs
Measured: Five uses of investigational devices, an average of one month
Invagination
Number of times when the external retention feature of the female condom is partly or fully pushed into the vagina during sexual intercourse
Measured: Five uses of investigational devices, an average of one month
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Monitoring of adverse event (locally at the perineum and/or vagina, per vaginal discharge, or any systemic reaction; and local reaction of the penis of the spouse) and adverse device event, as well as if Wondaleaf® ever breaks, if any portion of it retain intra-vaginally
Measured: Five uses of investigational device, an average of one month
Satisfaction
Satisfaction as assessed by the Satisfaction Questionnaire (Beksinska et al, 2013) - which assess using Likert scale ease of condom use/remove, comfort during sex, satisfaction with feeling of sex, in comparison to male condom and no condom, and preference with regards to male condom
Measured: Five uses of investigational device, an average of one month
Acceptability
Acceptability as assessed by four study-designed questions about Wondaleaf on whether Wondaleaf is a useful device for use worldwide and in Malaysia (very useful, moderately useful, not useful); if it is generally acceptable as female condom worldwide and in Malaysia (very acceptable, acceptable, unsure, not acceptable, highly unacceptable).
Measured: Five uses of investigational device, an average of one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2015 (estimated)
- Study startAug 2015
- Primary completionSep 2016
- Study completionSep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Clinical Research Centre, Malaysia
- Sponsor type
- University, hospital or other
- Collaborators
- Twin Catalyst Sdn Bhd
- Responsible party
- Sponsor
- Investigators
- Teck-Hock Toh, Principal investigator, Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health MalaysiaLoke-Meng Ong, Principal investigator, Clinical Research Centre, Penang General Hospital, Penang State Health Department, Ministry of Health MalaysiaShirin Hui Tan, Principal investigator, Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health MalaysiaSing Hong Chuo, Principal investigator, Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02593214
- Sponsor's protocol ID
- NMRR-15-333-24953
- Status last verified
- Aug 2016
- First submitted
- 27 Oct 2015
- Last updated
- 21 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Beksinska M, Joanis C, Manning J, Smit J, Callahan M, Deperthes B, Usher-Patel M. Standardized definitions of failure modes for female condoms. Contraception. 2007 Apr;75(4):251-5. doi: 10.1016/j.contraception.2006.10.003. Epub 2007 Feb 7.
PubMed 17362701Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect. 2004 Jun;80(3):167-73. doi: 10.1136/sti.2003.008441.
PubMed 15169996
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Asses the Performance and Safety of an Innovative Female Condom (Wondaleaf®) Among Healthy Married Couples
- ClinicalTrials.gov ID
- NCT02593214
- Acronym / sponsor ID
- NMRR-15-333-24953
- Conditions
- Pregnancy, Sexually Transmitted Disease
- Keywords
- Condoms, Female, Contraception, Barrier
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Clinical Research Centre, MalaysiaUniversity, hospital or other
- Collaborators
- Twin Catalyst Sdn Bhd
- Study start
- Aug 2015
- Primary completion
- Sep 2016 (actual)
- Study completion
- Sep 2016 (actual)
- First posted
- 2 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
General objective:
To assess the performance and safety profile of a novel innovative design of female condom (Wondaleaf®) among healthy married women.
Specific objectives :
- To determine the failure rate of Wondaleaf®, in terms of clinical breakage, non-clinical breakage, invagination, misdirection, and slippage.
- To determine the acceptability and satisfaction of use of Wondaleaf® by subjects and their spouses.
- To assess the safety profile of Wondaleaf®.
Detailed description
This is a single-centre clinical trial to assess the performance and safety profile of Wondaleaf® in healthy married women. Referrals from doctors and nurses in the Maternal and Child Health Clinics, Family Planning Clinics and private clinics in Sibu will be received. A total of 63 couples will be recruited to use Wondaleaf® and to study self-reported total clinical failure and total female condom failure and their components failure events of clinical breakage, non-clinical breakage, total breakage, slippage, misdirection, and invagination (as per World Health Organisation (WHO) Female Condom Technical Review Committee definition(1)). Secondary outcomes were safety parameters (retention of investigational device intra-vaginally should it break, complaint of sexually transmitted diseases, vaginal infection and/or urinary tract infections, all adverse events, serious adverse events, adverse device events and serious adverse device events, allergic reaction) as well as acceptability and satisfaction of the use of Wondaleaf®.
A focus group discussion will be held for the first two couples, to a maximum of five couples recruited based on the same inclusion and exclusion criteria will be asked to trial the process of training / counselling of using the condom, as well as completing the coital log. Experience gathered from these focus group testing and discussion, will be used to enhance the strength of this protocol.
Subsequently, each couple will be asked to use five Wondaleaf® and to complete a coital log at home after each condom use. Before putting on the investigational device, the subject must check for device or package breakage. During sexual intercourse, the couple ought to notice if any breakage of the condom has occurred, and if the female condom slips completely out of the vagina or the penis of male spouse is inserted between the condom and the vaginal wall as well as event of invagination (when the external retention feature of the female condom is partly or fully pushed into the vagina).
Each subject must maintain the wearing of investigational device for the entire process of intercourse until the male spouse ejaculate intra-vaginally. Following each ejaculation of the male spouse, the investigational devices must be checked for breakage before, during and after withdrawal of the condom from the vagina. A coital log must be completed by the couples within 12 hours after the use of each investigational device. Coital logs are used to obtain data for condom performance and safety. The five female investigational devices should be used within a period of four weeks. The used investigational devices shall be discarded safely in the usual and safe manner at home.
After the women completed five uses of Wondaleaf® or after four weeks (whichever occurs first), they will return to the clinic to return their coital log and to fill out an acceptability and satisfaction questionnaire. Any unused female investigational devices (i.e. the female condom) will be returned for counting purposes.
If the women were confirmed pregnant during study period, the subjects will be withdrawn from the study. The married couple will be referred for antenatal care of their choice.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Wondaleaf Arm | Experimental | Device: Wondaleaf®This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only. |
Who may qualify
- Ages
- 21 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Sexually active and legally married couples both between 21 and 45 years of age, and who have been in sexual relationship for at least 6 months;
- Married couples who are willing to participate (i.e. maintain sexually active and agree to have penile-vaginal intercourse with frequency sufficient to meet protocol requirements) and having signed informed consent form;
- Married women willing to have physical examination of the genitalia by the investigator (who is a medical doctor);
- Married women who are willing to take urine pregnancy test;
- Married couples who are planning to get pregnant, but do not mind delaying it;
Key exclusion criteria (16 listed)
- Female subject with known history of untreated or suspected sexually transmitted infection(s) including HIV/AIDS, vaginal or uterine infection(s), and/or urinary tract infections;
- Female subject with a history of abnormal Pap smear or cervical / uterine diseases;
- Female subject who is pregnant (established by urine pregnancy test), or desires to become so while participating in study;
- Either one of the married couple who have known history of allergy to the devices or materials used to manufacture the investigational devices, or any female or male condom, or lubricants that are used on the devices;
- Those staff who work directly under the investigators and/or employed directly by the device manufacturers, sponsor and study team;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wondaleaf®Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period | Device | Wondaleaf Arm |
Primary outcome
Total female condom failure
Time frame: Five uses of investigational devices, an average of one month
Number of times a non-clinical breakage, clinical breakage, or slippage occurs, or that is associated with misdirection, invagination, or any additional failure modes identified in the risk assessment
10 secondary outcomes
Total clinical failure
Time frame: Five uses of investigational devices, an average of one month
Clinical breakage
Time frame: Five uses of investigational devices, an average of one month
Non-clinical breakage
Time frame: Five uses of investigational devices, an average of one month
Total breakage
Time frame: Five uses of investigational devices, an average of one month
Slippage
Time frame: Five uses of investigational devices, an average of one month
Misdirection
Time frame: Five uses of investigational devices, an average of one month
Invagination
Time frame: Five uses of investigational devices, an average of one month
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: Five uses of investigational device, an average of one month
Satisfaction
Time frame: Five uses of investigational device, an average of one month
Acceptability
Time frame: Five uses of investigational device, an average of one month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2017.
- Background: PubMed 17362701Beksinska M, Joanis C, Manning J, Smit J, Callahan M, Deperthes B, Usher-Patel M. Standardized definitions of failure modes for female condoms. Contraception. 2007 Apr;75(4):251-5. doi: 10.1016/j.contraception.2006.10.003. Epub 2007 Feb 7.
- Background: PubMed 15169996Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect. 2004 Jun;80(3):167-73. doi: 10.1136/sti.2003.008441.
- Reproductive Health Supplies Coalition. Caucus on new and underused reproductive health technologies 2013.Link provided by the sponsor.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Teck-Hock Toh principal investigator
Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia
Loke-Meng Ong principal investigator
Clinical Research Centre, Penang General Hospital, Penang State Health Department, Ministry of Health Malaysia
Shirin Hui Tan principal investigator
Clinical Research Centre, Sibu Hospital, Sarawak State Health Department, Ministry of Health Malaysia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Wondaleaf® in people with Pregnancy and Sexually Transmitted Disease, run by Clinical Research Centre, Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total female condom failure (time frame: Five uses of investigational devices, an average of one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02593214, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2017.